Create Free Account

By creating account you will get access to hot stocks & personalised emails

Sigma Pharmaceuticals Ltd

Healthcare AU SIG

1.255AUD
-0.01(0.79%)

Last update at 2024-05-02T06:10:00Z

Day Range

1.251.27
LowHigh

52 Week Range

0.601.34
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-01-31 2022-01-31 2021-01-31 2020-01-31 2019-01-31
Type yearly yearly yearly yearly yearly
Date 2023-01-31 2022-01-31 2021-01-31 2020-01-31 2019-01-31
Income before tax 5.46M -8.30700M 51.75M -15.76000M 51.96M
Minority interest -1.21600M -0.90300M 0.69M 0.79M 1.03M
Net income 3.03M -6.33600M 59.76M -11.46700M 36.52M
Selling general administrative 82.62M 93.02M 68.79M 67.98M 63.60M
Selling and marketing expenses 210.38M 216.58M 214.61M 220.95M 232.50M
Gross profit 320.63M 296.51M 289.06M 269.60M 312.69M
Reconciled depreciation 30.34M 27.69M 30.99M 27.26M 13.52M
Ebit 26.86M 4.18M 34.20M -1.17400M 63.28M
Ebitda 57.19M 31.87M 65.19M 26.08M 76.81M
Depreciation and amortization 30.34M 27.69M 30.99M 27.26M 13.52M
Non operating income net other - - - - -
Operating income 26.86M 4.18M 34.20M -1.17400M 3.07M
Other operating expenses 3735.65M 3556.35M 3475.58M 3345.43M 4013.20M
Interest expense 14.41M 10.84M 11.82M 13.44M 11.85M
Tax provision 2.44M -1.97100M -9.50400M -4.29300M 14.92M
Interest income 0.60M 0.22M 11.46M 12.70M 11.07M
Net interest income -13.81000M -10.62000M -11.46300M -12.70200M -11.07000M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 2.44M -1.97100M -9.50400M -4.29300M 14.92M
Total revenue 3726.46M 3515.56M 3450.24M 3298.84M 4016.27M
Total operating expenses 329.82M 337.29M 314.39M 316.18M 309.62M
Cost of revenue 3405.83M 3219.06M 3161.19M 3029.24M 3703.58M
Total other income expense net -21.39600M -12.48800M 17.54M -14.58600M 48.88M
Discontinued operations - - - - -
Net income from continuing ops 3.03M -6.33600M 61.25M -11.46700M 37.04M
Net income applicable to common shares 1.81M -7.23900M 59.76M -12.33000M 36.52M
Preferred stock and other adjustments - - - - -
Breakdown 2024-01-31 2023-01-31 2022-01-31 2021-01-31 2020-01-31
Type yearly yearly yearly yearly yearly
Date 2024-01-31 2023-01-31 2022-01-31 2021-01-31 2020-01-31
Total assets 1404.13M 1174.07M 1248.28M 1205.62M 1212.07M
Intangible assets 20.00M 22.90M 25.09M 55.10M 32.41M
Earning assets - - - - -
Other current assets 14.91M 11.87M 50.17M 9.63M 20.17M
Total liab 531.52M 696.31M 759.50M 670.71M 735.33M
Total stockholder equity 870.77M 475.92M 487.19M 534.22M 475.95M
Deferred long term liab - - - - -
Other current liab 57.99M 57.45M 77.76M 82.32M 71.57M
Common stock 1682.37M 1234.46M 1225.45M 1219.91M 1216.56M
Capital stock 1637.02M 1234.46M 1225.45M 1219.91M 1216.56M
Retained earnings -769.17600M -761.58700M -741.13400M -690.92300M -753.80300M
Other liab - 4.91M 4.15M 7.24M 2.14M
Good will 89.06M 95.22M 102.96M 102.96M 102.96M
Other assets - 61.68M 59.40M 41.77M 27.18M
Cash 356.50M 16.65M 31.14M 16.13M 104.23M
Cash and equivalents - - - - -
Total current liabilities 371.28M 477.36M 457.61M 523.66M 575.95M
Current deferred revenue 0.14M 0.96M 1.89M 0.46M 1.42M
Net debt -219.86500M 210.34M 292.29M 199.10M 195.97M
Short term debt 9.79M 12.94M 25.69M 75.41M 142.97M
Short long term debt - 3.68M 15.38M 66.38M 135.02M
Short long term debt total 136.63M 226.99M 323.43M 215.23M 300.21M
Other stockholder equity -45.34900M 0.22M 2.87M 5.23M 13.20M
Property plant equipment - 290.92M 281.56M 288.29M 299.36M
Total current assets 912.50M 685.85M 761.63M 702.20M 735.95M
Long term investments 13.62M 16.08M 17.63M 15.30M 14.22M
Net tangible assets - 357.68M 359.14M 376.16M 340.59M
Short term investments - 0.00000M 0.01M 0.00000M -
Net receivables 319.96M 332.48M 358.68M 327.30M 296.05M
Long term debt - 80.00M 165.00M 0.00000M 115.19M
Inventory 221.13M 324.85M 321.64M 349.14M 315.49M
Accounts payable 303.36M 406.01M 352.27M 365.47M 359.99M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 2.92M 3.04M 2.87M 5.23M 13.20M
Additional paid in capital - - - - -
Common stock total equity - - - 1219.91M 1216.56M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1.19M 1.31M 0.78M 1.43M 2.18M
Deferred long term asset charges - - - - -
Non current assets total 491.63M 488.23M 486.65M 503.42M 476.12M
Capital lease obligations 136.63M 143.30M 143.06M 148.85M 50.00M
Long term debt total - 214.04M 297.74M 139.82M 157.24M
Breakdown 2023-01-31 2022-01-31 2021-01-31 2020-01-31 2019-01-31
Type yearly yearly yearly yearly yearly
Date 2023-01-31 2022-01-31 2021-01-31 2020-01-31 2019-01-31
Investments -28.60400M -2.38700M -6.33200M -7.14500M -3.02500M
Change to liabilities 53.54M -7.11200M 5.14M -133.18400M -33.70700M
Total cashflows from investing activities -28.60400M -16.59200M 98.76M -68.44000M -101.60600M
Net borrowings -101.88000M 148.62M -264.56400M -77.20800M 119.99M
Total cash from financing activities -116.94100M 128.89M -265.71100M -100.56600M 83.47M
Change to operating activities 16.64M -51.52300M 6.69M 8.23M -6.63700M
Net income 3.03M -7.23900M 59.76M -11.46700M 36.52M
Change in cash -2.80100M 66.02M -154.48300M 31.62M -9.63900M
Begin period cash flow 15.77M -50.25100M 104.23M 72.61M 82.25M
End period cash flow 12.97M 15.77M -50.25100M 104.23M 72.61M
Total cash from operating activities 33.36M 27.69M 12.47M 200.62M 8.47M
Issuance of capital stock 0.88M 0.20M 0.49M 5.28M 8.61M
Depreciation 30.34M 27.69M 30.99M 27.26M 13.52M
Other cashflows from investing activities 0.80M -0.00100M 175.80M -11.29600M 6.56M
Dividends paid 15.94M 19.93M 1.59M 30.71M 40.98M
Change to inventory -3.21100M 27.50M -33.64500M 27.78M 7.20M
Change to account receivables 27.50M -30.73200M -30.92500M 285.75M -11.79600M
Sale purchase of stock 0.88M 0.20M -0.05000M -0.05000M -4.14400M
Other cashflows from financing activities -16.88000M 148.62M -14.56400M -9.78000M 119.99M
Change to netincome 23.43M 9.39M -20.82400M 6.33M 1.73M
Capital expenditures 29.40M 14.20M 77.03M 57.14M 108.16M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.60M 0.22M 0.36M 0.74M 0.78M
Stock based compensation - - - - -
Other non cash items -33.36300M -20.45200M -90.74900M -14.92800M -50.04200M
Free cash flow 3.96M 13.49M -64.56100M 143.48M -99.69300M

Fundamentals

  • Previous Close 1.26
  • Market Cap2059.42M
  • Volume1291627
  • P/E Ratio-
  • Dividend Yield0.80%
  • EBITDA45.78M
  • Revenue TTM3322.06M
  • Revenue Per Share TTM3.24
  • Gross Profit TTM 254.41M
  • Diluted EPS TTM-

Peer Comparison

Sector: Healthcare Industry: Medical Distribution

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
SIG
Sigma Pharmaceuticals Ltd		 -0.01 0.79% 1.25 - 75.19 0.62 2.39 0.55 34.94
EBO
EBOS Group Ltd		 -0.19 0.59% 32.09 23.88 22.99 0.49 2.63 0.55 12.04
PGC
Paragon Care Ltd		 - -% 0.33 16.25 6.12 0.70 0.88 1.09 10.59

Reports Covered

Stock Research & News

View All

Profile

Sigma Healthcare Limited, together with its subsidiaries, engages in the wholesale distribution of pharmaceutical goods and medical consumables to community pharmacies primarily in Australia. The company operates various aligned pharmacies, including branded pharmacies under the Amcal, Discount Drug Stores, Guardian, and PharmaSave brands. It also provides retail support services to its branded network of pharmacy members; dose administration aid services; and third and fourth-party logistics services to pharmaceutical manufacturers and other supplier partners. The company was founded in 1912 and is headquartered in Clayton, Australia.

Sigma Pharmaceuticals Ltd

2125 Dandenong Road, Clayton, VIC, Australia, 3168

Key Executives

Name Title Year Born
Mr. Vikesh Ramsunder B.Com. CEO, MD & Director 1971
Mr. Nigel Simonsz Chief Financial Officer NA
Mr. Martin Hawkins Chief Information Officer NA
Ms. Kara McGowan Company Sec. & Gen. Counsel NA
Mr. Mark Conway B.Com., M.B.A. Chief Financial Officer NA
Ms. Kara McGowan A.C.I.S., L.L.B. Company Secretary & General Counsel NA
Mr. Gary Woodford Head of Corporate Affairs NA
Mr. Mark Conway B.Com., M.B.A. Chief Financial Officer NA
Ms. Kara McGowan A.C.I.S., L.L.B. Company Secretary & General Counsel NA
Mr. Gary Woodford Head of Corporate Affairs NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).

Our Company

Useful Links

Contact Us

Market Research

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.